Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

一种新的肥胖症治疗方法不再以神经元为靶点，而是针对大脑中的支持细胞，从而在不引起恶心的情况下实现减重和更好的血糖控制。人体试验有望在几年内开始。 目前市场上的减肥和糖尿病药物通常无法帮助患者实现长期减重。胰高血糖素样肽-1（Glucagon-like ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

三项最新研究表明，胰高血糖素样肽-1（Glucagon-like peptide-1, GLP-1）药物，如 Ozempic（奥земпик），可能显著降低中风死亡率，改善脑损伤后的恢复，并可能降低整体中风风险。 在神经介入手术学会（Society ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in ...